Trademark Information

Application ID
Status
Date of Application
30 June 2005
Classes
5
Proprietor
F 265, Solaris I, Saki Vihar Road, Andheri (East), 400 072
Agent
Chandrakant & Co.[6494]
Mr. Santosh Sakpal, #704, Nakshtra Tower, Mhada Bldg No.1, Shailendra Nagar, Nr Post Office, Dahisar East, Mumbai 400068
Type
Device
State
Maharashtra
Country
Filing Mode
Branch Office
IP Office
MUMBAI
Used Since
25 June 2005
Valid / Upto
30 June 2015
Description
[Class : 5] Medicinal And Pharmaceuticals Preparations.

Image (DEVICE)

Painmol Device mark 1368032 Trademark

Uploaded Documents

1 Additional Representation Sheet 29 Jun 2005
1 Journal Copy 29 Jun 2005
10 Additional Representation Sheet 30 Jun 2012
10 TM-1 30 Jun 2012
2 Certificate 29 Jun 2005
2 Examination Report 29 Jun 2005
3 Additional Representation Sheet 29 Jun 2005
3 Examination Report 29 Jun 2005
4 Journal Copy 29 Jun 2005
4 Power of Attorney 29 Jun 2005
5 Note Sheet 29 Jun 2005
5 TM-1 29 Jun 2005
6 Note Sheet 29 Jun 2005
6 TM-1 29 Jun 2005
7 Certificate 29 Jun 2005
7 Other Documents 29 Jun 2005
8 Other Documents 29 Jun 2005
8 Power of Attorney 29 Jun 2005
9 Additional Representation Sheet 30 Jun 2012
9 TM-1 30 Jun 2012

Correspondence and Notices

1 O3 NOTICE 2024316 1131794 22 Apr 2015

Frequently Asked Questions

What is the application date as per IP India website?

As per IP India data the trademark was applied on 30 June 2005.

Who has filed the trademark application with the TMO?

UNIBIOS LABORATORIES applied for Painmol.

What is the listed class of the Painmol with IP India?

Listed class of trademark Painmol is 5.

As per IP india what is the stage of trademark application?

Painmol is on the Removed stage of the trademark process.

What is the Serial number provided by the trademark data?

Serial Number provided to trademark application is 1368032

Who filed the trademark on behalf of the proprietor?

Trademark application was filed by the following attorney agent:
Chandrakant & Co

How is the Painmol categorized?

The trademark is categorized as DEVICE.